HCG ac­quires 12% eq­uity stake in ISSL

BioSpectrum (India) - - FINANCE NEWS -

Bengaluru-based on­col­ogy chain Health­Care Global En­ter­prises Ltd has ac­quired a 12 per cent eq­uity stake in In­ter­na­tional Stem­cell Ser­vices Ltd (ISSL) in a se­condary deal that saw its ex­ist­ing share­hold­ers di­vest­ing some of their hold­ings. Health­Care Global, which has ac­quired 10,860 eq­uity shares of ISSL for Rs 56 lakh in an all-cash deal, will help the com­pany de­velop treat­ment for cancer.

Bengaluru-based ISSL is in­volved in stem cell re­search. It of­fers stem cell bank­ing for re­gen­er­a­tive medicine, in­clud­ing um­bil­i­cal cord blood stem cells bank­ing and mes­enchy­mal stem cells bank­ing from um­bil­i­cal cord, stem cell ther­a­pies, and vac­cine ther­a­pies for cancer pa­tients. It also of­fers bank­ing of bone mar­row stem cells, pe­riph­eral blood mo­bi­lized stem cells, stem cells from lipo as­pi­rate, and stem cell ex­pan­sion and dif­fer­en­ti­a­tion. Health­Care Global op­er­ates 23 cancer care cen­tres un­der the HCG brand and fer­til­ity cen­tres un­der the Mi­lann brand in In­dia. It also op­er­ates multi-spe­cial­ity hos­pi­tals in Ahmed­abad, Bhav­na­gar, Ra­jkot, and Vado­dara in Gu­jarat.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.